关于公司
Replimune is pioneering the development of a novel class of tumor-directed oncolytic immunotherapies designed to deliver transformational results for difficult-to-treat cancers.
US
未知
未验证公司
业务透明度
- 未验证公司信息
- 向他们的客户询问评论
- 没有回复负面评论